Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

The primary objective of this study is to evaluate the utility of [18F]-DOPA PET to provide improved presurgical planning and distinguish between focal and diffuse forms of HI. The investigators will perform descriptive analysis, relying on visual analysis to diagnose and localize a focal lesion. Our findings will be compared to surgical histopathology to determine sensitivity and specificity or this technique. The investigators will also track patient surgical outcomes, specifically whether the patient is surgically "cured" or still requires medical management to control residual hypoglycemia.


Study summary:

Hyperinsulinemic hypoglycemia is caused by low glucose due to excessive insulin secretion and remains difficult to treat because of the requirement for extensive amounts of glucose and the lack of effective long-term medical therapy. Correct diagnosis, localization, and limited excision of the focal lesion will result in a complete cure of the patient. In contrast, medically unresponsive diffuse disease requires a near total pancreatectomy, greatly increasing the risk of future diabetes mellitus. Fortunately, [18F]-DOPA PET has been shown to be a useful noninvasive imaging method for distinguishing between focal and diffuse forms of hyperinsulinemic hypoglycemia. In this study, the investigators seek to validate the effectiveness of using PET/MR and PET/CT with F-DOPA to accurately and reliably detect and localize disease.


Criteria:

Inclusion Criteria: - All Patients clinically diagnosed with Hyperinsulinemia of any age - Patients in need of PET scan - Patients that require sedation - Patients that do not require sedation Exclusion Criteria: Subjects presenting with any of the following will not be included in the study: - Patients without Hyperinsulinemia - Patients who are or may be pregnant - Serious intercurrent medical illness other than hypoglycemia that precludes having the scan either because of patient instability or concerns about potential toxicity. - Patient's requiring emergency surgical intervention that would be inappropriately delayed by [18F]-DOPA PET imaging.


NCT ID:

NCT02533219


Primary Contact:

Victor Seghers, PhD, MD
Phone: 832-822-0429
Email: vjsegher@texaschildrens.org


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States

Victor Seghers, PhD, MD
Phone: 832-822-0429
Email: vjsegher@texaschildrens.org

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.